A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.

Bae-Jump VL, Sill MW, Gehrig PA, Merker JD, Corcoran DL, Pfefferle AD, Hayward MC, Walker JL, Hagemann AR, Waggoner SE, O'Cearbhaill RE, McDonald ME, Edelson MI, DiSilvestro PA, McNally AL, Fleury A, Littell RD, Ueland FR, Lankes HA, Aghajanian C

Open source

DOI: 10.1016/j.ygyno.2025.03.003
Published: 2025 Apr
Container: Gynecologic oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2025.03.003,
  title = {A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.},
  author = {Bae-Jump VL and Sill MW and Gehrig PA and Merker JD and Corcoran DL and Pfefferle AD and Hayward MC and Walker JL and Hagemann AR and Waggoner SE and O'Cearbhaill RE and McDonald ME and Edelson MI and DiSilvestro PA and McNally AL and Fleury A and Littell RD and Ueland FR and Lankes HA and Aghajanian C},
  year = {2025},
  journal = {Gynecologic oncology},
  doi = {10.1016/j.ygyno.2025.03.003},
  url = {https://doi.org/10.1016/j.ygyno.2025.03.003}
}

RIS

TY  - JOUR
TI  - A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
AU  - Bae-Jump VL
AU  - Sill MW
AU  - Gehrig PA
AU  - Merker JD
AU  - Corcoran DL
AU  - Pfefferle AD
AU  - Hayward MC
AU  - Walker JL
AU  - Hagemann AR
AU  - Waggoner SE
AU  - O'Cearbhaill RE
AU  - McDonald ME
AU  - Edelson MI
AU  - DiSilvestro PA
AU  - McNally AL
AU  - Fleury A
AU  - Littell RD
AU  - Ueland FR
AU  - Lankes HA
AU  - Aghajanian C
PY  - 2025
JO  - Gynecologic oncology
DO  - 10.1016/j.ygyno.2025.03.003
UR  - https://doi.org/10.1016/j.ygyno.2025.03.003
ER  -

APA

VL, B., MW, S., PA, G., JD, M., DL, C., AD, P., MC, H., JL, W., AR, H., SE, W., RE, O., ME, M., MI, E., PA, D., AL, M., A, F., RD, L., FR, U., HA, L., & C, A. (2025). A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2025.03.003

Source records

pubmed · retrieved 2026-09-26T16:48:13.502Z